ArticleACS omega2023
Hypophyllanthin and Phyllanthin from
Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 17 citations in OpenAlex.
- African Medicinal Plants Targeting Triple-Negative Breast Cancer (TNBC): A Systematic Review of Ethnobotanical Surveys, Phytochemistry and Anti-TNBC Studies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Combinatorial effects of curcumin, morin, and phyllanthin in MDA-MB-231 and MCF-7 breast cancer cell lines.Indian journal of pharmacology · 2026Article
- Fenugreek seed extract-doxorubicin synergy against hepatocellular carcinoma in HepG2 cells: in vitro and in silico mechanistic studies.BMC complementary medicine and therapies · 2026Article
- Synergistic anticancer activity of frankincense aqueous extract with sorafenib in HepG2 cells and its UHPLC-QTOF-MS/MS-based metabolomic profiling.Scientific reports · 2026Article
- New indole diketopiperazine from the fungus Penicillium chrysogenum.The Journal of antibiotics · 2026Article
- Chelidonine overcomes P-gp-mediated adriamycin resistance in MCF-7/ADR cells by inhibiting PDGFRChinese herbal medicines · 2026Article
- Unveiling the potency of ZnO and CuO nanocomposites in combating hepatocellular carcinoma by inducing cell death and suppressing migration.Scientific reports · 2025Article
- Biosynthesis of selenium nanoparticles as a potential therapeutic agent in breast cancer: G2/M arrest and apoptosis induction.Toxicology reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Doxorubicin (DOX) is a cornerstone chemotherapeutic agent for the treatment of several malignancies such as breast cancer; however, its activity is ameliorated by the development of a resistant phenotype.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.